| CORPORATIONS |
CORPORATIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| DISTRIBUTOR-CUSTOMERS |
DISTRIBUTOR-CUSTOMERS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| INDEPENDENT-LABORATORIES |
INDEPENDENT-LABORATORIES |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| LARGE-HOSPITAL-SYSTEMS |
LARGE-HOSPITAL-SYSTEMS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| PUBLIC-AND-PRIVATE-INSTITUTIONS |
PUBLIC-AND-PRIVATE-INSTITUTIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| RESEARCH-ORGANIZATIONS |
RESEARCH-ORGANIZATIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from VRAX graph: sed materials technology company to acquire partially their relevant proprietary technology, and we have no specific c… |
| ABT |
Abbott Laboratories |
72%
|
sed materials technology company to acquire partially their relevant proprietary technology, and we have no specific closing timeline as of the date of this report. After the acquisition, we will ado… |
| NCNA |
NuCana plc |
72%
|
Reciprocal relationship from NCNA graph: Reciprocal relationship from VRAX graph: regular healthcare consulting are still hindrances in some regions, especially third-world countries, which impedes t… |
| NCNA |
NuCana plc |
72%
|
regular healthcare consulting are still hindrances in some regions, especially third-world countries, which impedes the growth of the IVD market. Key Supplier Relationships We source our suppliers th… |
| QGEN |
Qiagen N.V. |
72%
|
n and T-cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, established pharmaceutical companies, and other in-vitro diagnostics companies. Many of our… |
| QGEN |
Qiagen N.V. |
72%
|
Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN g… |
| RY |
Royal Bank of Canada |
72%
|
Reciprocal relationship from RY graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from RY graph: Reciprocal relationship from VRAX graph: ribution partners and selling on our ow… |
| RY |
Royal Bank of Canada |
72%
|
ribution partners and selling on our own online platform. We are also seeking to grow the product offering to leverage our existing and growing distribution network. ViraxCare provides innovative med… |
| AG-PROFESSIONAL-CARDIAC-INC |
AG-PROFESSIONAL-CARDIAC-INC |
62%
|
en Receptor T cell (CAR-T) therapies, Myloid, Encephalomyelitis (ME) and post viral syndromes. This versatility will position ViraxImmune as a comprehensive platform capable of potentially addressing… |
| MEDICAL-DEVICE-COMPANY-LIMITED |
MEDICAL-DEVICE-COMPANY-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| NATURAL-SOURCE-GROUP |
NATURAL-SOURCE-GROUP |
62%
|
. This lease was subsequently modified in August 2023 and November 2023 to include additional rooms at BioCity. Lease expense for the year ended March 31, 2024 was GBP 27,521 . The annual rent as of … |
| NATURAL-SOURCE-GROUP-PTE-LIMITED |
NATURAL-SOURCE-GROUP-PTE-LIMITED |
62%
|
regular healthcare consulting are still hindrances in some regions, especially third-world countries, which impedes the growth of the IVD market. Key Supplier Relationships We source our suppliers th… |
| SHANGHAI-BIOTECHNOLOGY-DEVICES-LIMITED |
SHANGHAI-BIOTECHNOLOGY-DEVICES-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| SHANGHAI-BIOTECHNOLOGY-DEVICES-LTD |
SHANGHAI-BIOTECHNOLOGY-DEVICES-LTD |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| SHANGHAI-XITU-CONSULTING-CO-LIMITED |
SHANGHAI-XITU-CONSULTING-CO-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
